» Articles » PMID: 23405201

The Detergent-soluble Cytoplasmic Pool of Survivin Suppresses Anoikis and Its Expression is Associated with Metastatic Disease of Human Colon Cancer

Overview
Journal PLoS One
Date 2013 Feb 14
PMID 23405201
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Survivin is a component of the chromosomal passenger complex (CPC) that is essential for accurate chromosome segregation. Interfering with the function of Survivin in mitosis leads to chromosome segregation errors and defective cytokinesis. Survivin contains a Baculovirus IAP Repeat (BIR) and therefore was originally classified as inhibitor of apopotosis protein (IAP), yet its role in apoptosis after cellular stress remains largely unknown. We demonstrate here, that Survivin predominantly suppresses anoikis, a form of programmed cell death induced by loss of cellular adhesion to extracellular matrix. Interestingly, cells ectopically overexpressing EGFP-Survivin showed after loss of cell-matrix-interaction a decreased expression of IκB-α. Subsequent subcellular protein fractionation and immunoprecipitation experiments revealed that XIAP interacts with detergent-soluble Survivin which is known to cooperatively activate NF-κB signaling. Examination of the expression levels of detergent soluble Survivin in colorectal cancer cell lines and in colorectal cancerous tissues revealed that detergent soluble cytoplasmic Survivin levels correlated inversely with anoikis susceptibility in colorectal cancer. Therefore, the detergent soluble cytoplasmic Survivin might be a promising predictive biomarker for lymph node and distant metastases of colorectal cancer. We conclude that an anti-apoptotic function of detergent-soluble Survivin in interphase cells experiencing anoikis is mediated at least via XIAP/IκB-α/NF-κB signaling.

Citing Articles

Metabolic reprogramming and signaling adaptations in anoikis resistance: mechanisms and therapeutic targets.

He C, He J Mol Cell Biochem. 2025; .

PMID: 39821582 DOI: 10.1007/s11010-024-05199-3.


Development of a prognostic model for anoikis and identifies hub genes in hepatocellular carcinoma.

Zhong Z, Xie F, Yin J, Zhao H, Zhou Y, Guo K Sci Rep. 2023; 13(1):14723.

PMID: 37679418 PMC: 10484901. DOI: 10.1038/s41598-023-41139-9.


Expression of USP22 and the chromosomal passenger complex is an indicator of malignant progression in oral squamous cell carcinoma.

Liu T, Liu J, Chen Q, Jin S, Mi S, Shao W Oncol Lett. 2019; 17(2):2040-2046.

PMID: 30675271 PMC: 6341666. DOI: 10.3892/ol.2018.9837.


PARP6 acts as a tumor suppressor via downregulating Survivin expression in colorectal cancer.

Qi G, Kudo Y, Tang B, Liu T, Jin S, Liu J Oncotarget. 2016; 7(14):18812-24.

PMID: 26934315 PMC: 4951331. DOI: 10.18632/oncotarget.7712.


Use of a Novel Integrase-Deficient Lentivirus for Targeted Anti-Cancer Therapy With Survivin Promoter-Driven Diphtheria Toxin A.

Lin B, Gao A, Zhang R, Ma H, Shen H, Hu Q Medicine (Baltimore). 2015; 94(31):e1301.

PMID: 26252309 PMC: 4616595. DOI: 10.1097/MD.0000000000001301.


References
1.
Uren A, Wong L, Pakusch M, Fowler K, Burrows F, Vaux D . Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol. 2000; 10(21):1319-28. DOI: 10.1016/s0960-9822(00)00769-7. View

2.
Dohi T, Beltrami E, Wall N, Plescia J, Altieri D . Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 2004; 114(8):1117-27. PMC: 522254. DOI: 10.1172/JCI22222. View

3.
Qi G, Tuncel H, Aoki E, Tanaka S, Oka S, Kaneko I . Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep. 2009; 22(3):557-62. DOI: 10.3892/or_00000471. View

4.
Dohi T, Okada K, Xia F, Wilford C, Samuel T, Welsh K . An IAP-IAP complex inhibits apoptosis. J Biol Chem. 2004; 279(33):34087-90. DOI: 10.1074/jbc.C400236200. View

5.
Christmann M, Tomicic M, Origer J, Kaina B . Fen1 is induced p53 dependently and involved in the recovery from UV-light-induced replication inhibition. Oncogene. 2005; 24(56):8304-13. DOI: 10.1038/sj.onc.1208994. View